NADAC acquisition cost data for WELCHOL 3.75G PACKET. This is a brand-name medication — generic alternatives may be available at lower prices.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 65597090230 | $21.50 | 2021-04-21 | Rx |
| 65597090230 | $21.50 | 2021-04-21 | Rx |
| 65597090230 | $21.50 | 2021-04-21 | Rx |
| 65597090230 | $21.50 | 2021-04-21 | Rx |
| 65597090230 | $21.50 | 2021-04-21 | Rx |
| 65597090230 | $21.50 | 2021-04-21 | Rx |
| 65597090230 | $21.50 | 2021-04-21 | Rx |
| 65597090230 | $21.50 | 2021-04-21 | Rx |
| 65597090230 | $21.50 | 2021-04-21 | Rx |
| 65597090230 | $21.50 | 2021-04-21 | Rx |
Generic: Colesevelam HCl | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $102.1M | 143,195 | 36,178 | $5.33 |
| 2020 | $78.1M | 102,465 | 24,277 | $5.31 |
| 2021 | $38.5M | 50,751 | 12,159 | $5.47 |
| 2022 | $22.6M | 28,099 | 6,289 | $5.57 |
| 2023 | $9.7M | 10,674 | 2,778 | $5.40 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| New York | $1.2M | 1,281 | 255 |
| California | $1.1M | 1,073 | 284 |
| New Jersey | $531.6K | 434 | 117 |
| Florida | $527.0K | 545 | 165 |
| Pennsylvania | $507.8K | 573 | 131 |
| Texas | $473.0K | 520 | 158 |
| Georgia | $391.8K | 590 | 150 |
| South Carolina | $377.7K | 364 | 114 |
| North Carolina | $286.1K | 245 | 81 |
| Indiana | $273.6K | 354 | 80 |
| Maryland | $272.5K | 252 | 66 |
| Illinois | $269.5K | 236 | 66 |
| Virginia | $258.3K | 235 | 61 |
| Tennessee | $251.6K | 287 | 86 |
| Ohio | $247.9K | 265 | 67 |
| Connecticut | $205.1K | 169 | 40 |
| Kentucky | $174.3K | 258 | 72 |
| Massachusetts | $170.1K | 175 | 45 |
| Missouri | $169.3K | 230 | 67 |
| Alabama | $161.1K | 225 | 62 |
| Wisconsin | $150.3K | 121 | 38 |
| Mississippi | $141.6K | 262 | 74 |
| Louisiana | $132.5K | 206 | 59 |
| Oklahoma | $115.4K | 121 | 31 |
| Nebraska | $108.7K | 216 | 45 |
| Minnesota | $101.9K | 79 | 31 |
| Michigan | $95.9K | 114 | 32 |
| Kansas | $94.3K | 197 | 38 |
| Iowa | $93.4K | 169 | 47 |
| Arkansas | $75.1K | 151 | 32 |
| West Virginia | $66.3K | 99 | 25 |
| Washington | $63.2K | 67 | 22 |
| Arizona | $59.1K | 49 | 18 |
| South Dakota | $57.8K | 81 | 23 |
| Colorado | $51.1K | 60 | 21 |
| Nevada | $45.8K | 33 | 11 |
| Hawaii | $39.9K | 27 | N/A |
| Rhode Island | $32.3K | 36 | N/A |
| North Dakota | $32.1K | 34 | N/A |
| Vermont | $28.7K | 21 | N/A |
| Delaware | $27.5K | 29 | 11 |
| District of Columbia | $27.1K | 32 | N/A |
| Idaho | $26.8K | 22 | N/A |
| New Hampshire | $26.1K | 30 | N/A |
| Utah | $20.6K | 29 | N/A |
| Oregon | $19.3K | 27 | 12 |
| New Mexico | $15.8K | 20 | N/A |
| Montana | $10.4K | 19 | N/A |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.
Explore More Data Tools
For adjacent public-data tools, methodology notes, and network updates, visit DataPeek Facts.